湿性老年黄斑部病变市场：KOL 洞察

随着罗氏 Vabysmo（Bayer/Regeneron Eylea 的竞争对手）的推出，一线药物的模式正在改变。 另一方面，标籤外阿瓦斯汀仍然是一种具有成本效益的选择，但新的进展可能会减少其使用。 展望未来，重点是延长治疗间隔、改善视力和侵入性较小的选择，突显基因疗法、酪胺酸激□抑制剂和 D 4517.2 和 Axpaxli 等创新药物的潜力。 在 wAMD 治疗的这个关键时刻，需要采取策略重点来解决未满足的需求并采用新的治疗途径。

本报告考察了全球湿性老年黄斑部病变市场，并提供了市场概述，包括已上市的治疗方法、管道趋势和未来前景。

目录

执行摘要

处理演算法

研究目的

VEGF抑制剂

• 市售治疗方法

VEGF抑制剂

• 标籤外使用市售治疗方法
• 管道疗法

酪胺酸激□抑制剂

• 管道疗法

基因治疗

• 管道疗法

未来的治疗范例

• 主要见解摘要
  • 开发治疗 wAMD 药物的製药公司应专注于治疗持续时间、给药便利性、安全性和新的治疗途径。

附录

With the introduction of Roche's Vabysmo challenging Bayer/Regeneron's Eylea, the dynamics of first-line choices are shifting. Meanwhile, off-label Avastin remains a cost-effective option, though its usage may wane with new advancements. As we look to the future, the focus sharpens on longer treatment intervals, improved visual acuity, and less invasive options, highlighting the potential of gene therapies, tyrosine kinase inhibitors, and innovative drugs like D 4517.2 and Axpaxli. This pivotal moment in wAMD treatment calls for a strategic pivot towards addressing unmet needs and embracing novel therapeutic pathways.

Table of Contents

Executive summary (14)

Treatment algorithm

Research objectives (2)

VEGF inhibitors (71)

• Marketed therapies (71)
  • Vabysmo (faricimab; Roche) (21)
  • Eylea (aflibercept; Bayer/Regeneron Pharmaceuticals) (21)
  • Lucentis (ranibizumab; Roche/Novartis) (18)
  • Beovu (brolucizumab; Novartis) (11)

VEGF inhibitors (70)

• Marketed therapies used off label (13)
  • Avastin (bevacizumab; Roche) (13)
• Pipeline therapies (57)
  • Sozinibercept (OPT-302; Opthea) (16)
  • D-4517.2 (Asvattha Therapeutics) (17)
  • Lytenava (bevacizumab ophthalmic; Outlook Therapeutics) (14)
  • Yesafili (aflibercept biosimilar; Momenta Pharmaceuticals/Viatris/Biocon) (10)

Tyrosine kinase inhibitors (24)

• Pipeline therapies (24)
  • Axpaxli (axitinib intravitreal implant/OTX-TKI; Ocular Therapeutix) (12)
  • Vorolanib (Equinox Sciences/EyePoint Pharmaceuticals) (12)

Gene therapy (32)

• Pipeline therapies (32)
  • ABBV-RGX-314 (REGENXBIO/AbbVie) (22)
  • Ixoberogene soroparvovec (Ixo-vec; Adverum Biotechnologies) (10)

Future treatment paradigm (15)

• Key insights summary (15)
  • Pharma companies developing wAMD therapies should focus on treatment duration, ease of administration, safety and new therapeutic pathways (3)

Appendix (3)

• KOL details (3)
  • KOLs from the USA (1)
  • KOLs from Europe (1)